New cancer drug BNT3214 enters first human trials

NCT ID NCT07455734

Recruiting now Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Mar 09, 2026 · Last updated May 23, 2026 · Updated 10 times

Summary

This study tests a new drug called BNT3214 for the first time in people with advanced solid tumors. The goal is to find the safest dose and see if it can shrink tumors. About 533 adults will take part in three phases: first finding the right dose, then testing it in different cancer types.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Epworth HealthCare
NOT_YET_RECRUITING

Richmond, 3121, Australia
Monash Medical Centre Clayton
NOT_YET_RECRUITING

Fitzroy, 3065, Australia
Nanfang Hospital of Southern Medical University
RECRUITING

Guangzhou, 510515, China
National Taiwan University Hospital
NOT_YET_RECRUITING

Taipei, 100225, Taiwan
Shanghai East Hospital
RECRUITING

Shanghai, 200120, China

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR CANCER